Latest news

Final results of the rights issue

Posted on Jan 10, 2017

Oslo, 10 January, 2017 – Reference is made to the previous announcements by PCI Biotech Holding ASA (“PCI Biotech” or the “Company”) in respect of the fully underwritten rights issue of 10,000,000 new shares in the Company (the “Rights Issue”). The subscription period for the Rights Issue expired at 16:30 CET on 5 January 2017. At […]

PCI Biotech presentation from Biotech Showcase 2017

Posted on Jan 10, 2017

Oslo, Norway, January 10, 2017 – The PCI Biotech presentation from Biotech Showcase™ 2017 is available at the link below. The presentation was held Monday, January 9, 2017 at 4:00pm PT, by Dr. Per Walday, PCI Biotech’s CEO, at the Hilton San Francisco Union Square, California, US.  170109 Biotech Showcase Presentation by PCIB

The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway

Posted on Jan 6, 2017

Oslo (Norway), January 6, 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and Ultimovacs, a pharmaceutical company developing novel immunotherapy against cancer, today announced that they are awarded NOK 500,000 for further development of the existing preclinical research collaboration. The purpose of the collaboration is to utilise the companies’ complementary scientific platforms […]